Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
Abstract Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated heterogeneous disease and is characterized by peritumoral immune infiltrate. Adoptive T-cell therapy (ACT) has emerged as a potential therapeutic strategy for NPC. However, the tumor microenvironment remains a major ro...
Main Authors: | Corey Smith, Margaret McGrath, Michelle A. Neller, Katherine K. Matthews, Pauline Crooks, Laetitia Le Texier, Benedict Panizza, Sandro Porceddu, Rajiv Khanna |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-03-01
|
Series: | npj Precision Oncology |
Online Access: | https://doi.org/10.1038/s41698-021-00162-7 |
Similar Items
-
'Off-the-shelf’ allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies
by: Debottam Sinha, et al.
Published: (2021-02-01) -
A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
by: Jin Bian, et al.
Published: (2022-01-01) -
Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
by: Darren Wan-Teck Lim, et al.
Published: (2023-05-01) -
Retracted: A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
by: Applied Bionics and Biomechanics
Published: (2023-01-01) -
Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response
by: Corey Smith, et al.
Published: (2017-02-01)